C-peptide vs Larazotide
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and Larazotide (Larazotide acetate (AT-1001)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | C-peptide | Larazotide |
|---|---|---|
| Category | Pain Management | Gastrointestinal |
| Full Name | Connecting peptide (C-peptide) | Larazotide acetate (AT-1001) |
| Molecular Weight | 3020.3 Da | N/A |
| Half-Life | ~20-30 min | short; designed for local gut action |
| Amino Acids | 31 | 8 |
| Typical Dose | no approved analgesic dose|research-only | 0.5-4 mg TID (clinical studies) |
| Route | IV|subQ | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 40 |
| Research Status | Pre-clinical | Clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Larazotide Benefits
- ✓tight-junction-support
- ✓reduced-permeability
- ✓symptom-reduction
- ✓barrier-protection
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Larazotide Dosing
0.5-4 mg orally before meals in clinical trials|typically three times daily|short-course or chronic study protocols
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Larazotide Side Effects
- ⚠headache
- ⚠nausea
- ⚠abdominal discomfort
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Larazotide
Clinical and translational studies suggest larazotide can reduce antigen passage across the epithelium and improve gut barrier function. It is one of the better-known peptides for intestinal permeability and barrier-focused gastrointestinal therapy.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.